-
Something wrong with this record ?
Virological characteristics of the SARS-CoV-2 BA.2.86 variant
T. Tamura, K. Mizuma, H. Nasser, S. Deguchi, M. Padilla-Blanco, Y. Oda, K. Uriu, JEM. Tolentino, S. Tsujino, R. Suzuki, I. Kojima, N. Nao, R. Shimizu, L. Wang, M. Tsuda, M. Jonathan, Y. Kosugi, Z. Guo, AA. Hinay, O. Putri, Y. Kim, YL. Tanaka, H....
Language English Country United States
Document type Journal Article
NLK
Cell Press Free Archives
from 2007-03-15 to 1 year ago
Free Medical Journals
from 2007 to 1 year ago
- MeSH
- Amino Acids MeSH
- COVID-19 * MeSH
- Kinetics MeSH
- Cricetinae MeSH
- Mutation MeSH
- SARS-CoV-2 genetics MeSH
- Animals MeSH
- Check Tag
- Cricetinae MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
In late 2023, several SARS-CoV-2 XBB descendants, notably EG.5.1, were predominant worldwide. However, a distinct SARS-CoV-2 lineage, the BA.2.86 variant, also emerged. BA.2.86 is phylogenetically distinct from other Omicron sublineages, accumulating over 30 amino acid mutations in its spike protein. Here, we examined the virological characteristics of the BA.2.86 variant. Our epidemic dynamics modeling suggested that the relative reproduction number of BA.2.86 is significantly higher than that of EG.5.1. Additionally, four clinically available antivirals were effective against BA.2.86. Although the fusogenicity of BA.2.86 spike is similar to that of the parental BA.2 spike, the intrinsic pathogenicity of BA.2.86 in hamsters was significantly lower than that of BA.2. Since the growth kinetics of BA.2.86 are significantly lower than those of BA.2 both in vitro and in vivo, the attenuated pathogenicity of BA.2.86 is likely due to its decreased replication capacity. These findings uncover the features of BA.2.86, providing insights for control and treatment.
1st Medical Faculty at Biocev Charles University Vestec Prague Czechia
AMED CREST Japan Agency for Medical Research and Development Tokyo Japan
Center for Animal Disease Control University of Miyazaki Miyazaki Japan
Center for iPS Cell Research and Application Kyoto University Kyoto Japan
CREST Japan Science and Technology Agency Kawaguchi Japan
Department of Cancer Pathology Faculty of Medicine Hokkaido University Sapporo Japan
Department of Microbiology and Immunology Faculty of Medicine Hokkaido University Sapporo Japan
Department of Veterinary Science Faculty of Agriculture University of Miyazaki Miyazaki Japan
Facultad de Ciencias de la Salud Universidad Cardenal Herrera CEU CEU Universities Valencia Spain
Faculty of Medicine Suez Canal University Ismailia Egypt
Faculty of Natural Science Imperial College London London UK
Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
Graduate School of Frontier Sciences The University of Tokyo Kashiwa Japan
Graduate School of Medicine and Veterinary Medicine University of Miyazaki Miyazaki Japan
Graduate School of Medicine Hokkaido University Sapporo Japan
Graduate School of Medicine The University of Tokyo Tokyo Japan
Indonesia International Institute for Life Sciences Jakarta Indonesia
Institute for Chemical Reaction Design and Discovery Hokkaido University Sapporo Japan
Institute for the Advancement of Higher Education Hokkaido University Sapporo Japan
Institute for Vaccine Research and Development Hokkaido University Sapporo Japan
Laboratory of Virus Control Research Institute for Microbial Diseases Osaka University Suita Japan
One Health Research Center Hokkaido University Sapporo Japan
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007142
- 003
- CZ-PrNML
- 005
- 20240423155740.0
- 007
- ta
- 008
- 240412s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.chom.2024.01.001 $2 doi
- 035 __
- $a (PubMed)38280382
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Tamura, Tomokazu $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Graduate School of Medicine, Hokkaido University, Sapporo, Japan; School of Medicine, Hokkaido University, Sapporo, Japan; Institute for the Advancement of Higher Education, Hokkaido University, Sapporo, Japan
- 245 10
- $a Virological characteristics of the SARS-CoV-2 BA.2.86 variant / $c T. Tamura, K. Mizuma, H. Nasser, S. Deguchi, M. Padilla-Blanco, Y. Oda, K. Uriu, JEM. Tolentino, S. Tsujino, R. Suzuki, I. Kojima, N. Nao, R. Shimizu, L. Wang, M. Tsuda, M. Jonathan, Y. Kosugi, Z. Guo, AA. Hinay, O. Putri, Y. Kim, YL. Tanaka, H. Asakura, M. Nagashima, K. Sadamasu, K. Yoshimura, Genotype to Phenotype Japan (G2P-Japan) Consortium, A. Saito, J. Ito, T. Irie, S. Tanaka, J. Zahradnik, T. Ikeda, K. Takayama, K. Matsuno, T. Fukuhara, K. Sato
- 520 9_
- $a In late 2023, several SARS-CoV-2 XBB descendants, notably EG.5.1, were predominant worldwide. However, a distinct SARS-CoV-2 lineage, the BA.2.86 variant, also emerged. BA.2.86 is phylogenetically distinct from other Omicron sublineages, accumulating over 30 amino acid mutations in its spike protein. Here, we examined the virological characteristics of the BA.2.86 variant. Our epidemic dynamics modeling suggested that the relative reproduction number of BA.2.86 is significantly higher than that of EG.5.1. Additionally, four clinically available antivirals were effective against BA.2.86. Although the fusogenicity of BA.2.86 spike is similar to that of the parental BA.2 spike, the intrinsic pathogenicity of BA.2.86 in hamsters was significantly lower than that of BA.2. Since the growth kinetics of BA.2.86 are significantly lower than those of BA.2 both in vitro and in vivo, the attenuated pathogenicity of BA.2.86 is likely due to its decreased replication capacity. These findings uncover the features of BA.2.86, providing insights for control and treatment.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a křečci praví $7 D006224
- 650 12
- $a COVID-19 $7 D000086382
- 650 _2
- $a SARS-CoV-2 $x genetika $7 D000086402
- 650 _2
- $a aminokyseliny $7 D000596
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a mutace $7 D009154
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mizuma, Keita $u Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Nasser, Hesham $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan; Faculty of Medicine, Suez Canal University, Ismailia, Egypt
- 700 1_
- $a Deguchi, Sayaka $u Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- 700 1_
- $a Padilla-Blanco, Miguel $u First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia; Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain
- 700 1_
- $a Oda, Yoshitaka $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Uriu, Keiya $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Tolentino, Jarel E M $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
- 700 1_
- $a Tsujino, Shuhei $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Suzuki, Rigel $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan
- 700 1_
- $a Kojima, Isshu $u Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Nao, Naganori $u Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
- 700 1_
- $a Shimizu, Ryo $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- 700 1_
- $a Wang, Lei $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan
- 700 1_
- $a Tsuda, Masumi $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan
- 700 1_
- $a Jonathan, Michael $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
- 700 1_
- $a Kosugi, Yusuke $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Guo, Ziyi $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Hinay, Alfredo A $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Putri, Olivia $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Indonesia International Institute for Life Sciences (i3L), Jakarta, Indonesia
- 700 1_
- $a Kim, Yoonjin $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Faculty of Natural Science, Imperial College London, London, UK
- 700 1_
- $a Tanaka, Yuri L $u Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan
- 700 1_
- $a Asakura, Hiroyuki $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Nagashima, Mami $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Sadamasu, Kenji $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Yoshimura, Kazuhisa $u Tokyo Metropolitan Institute of Public Health, Tokyo, Japan
- 700 1_
- $a Saito, Akatsuki $u Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan; Center for Animal Disease Control, University of Miyazaki, Miyazaki, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan
- 700 1_
- $a Ito, Jumpei $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- 700 1_
- $a Irie, Takashi $u Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
- 700 1_
- $a Tanaka, Shinya $u Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan. Electronic address: tanaka@med.hokudai.ac.jp
- 700 1_
- $a Zahradnik, Jiri $u First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia. Electronic address: jiri.zahradnik2@gmail.com
- 700 1_
- $a Ikeda, Terumasa $u Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Electronic address: ikedat@kumamoto-u.ac.jp
- 700 1_
- $a Takayama, Kazuo $u Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan. Electronic address: kazuo.takayama@cira.kyoto-u.ac.jp
- 700 1_
- $a Matsuno, Keita $u Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan. Electronic address: matsuk@czc.hokudai.ac.jp
- 700 1_
- $a Fukuhara, Takasuke $u Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Graduate School of Medicine, Hokkaido University, Sapporo, Japan; School of Medicine, Hokkaido University, Sapporo, Japan; Institute for the Advancement of Higher Education, Hokkaido University, Sapporo, Japan; AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Japan. Electronic address: fukut@pop.med.hokudai.ac.jp
- 700 1_
- $a Sato, Kei $u Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; CREST, Japan Science and Technology Agency, Kawaguchi, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Electronic address: keisato@g.ecc.u-tokyo.ac.jp
- 710 2_
- $a Genotype to Phenotype Japan (G2P-Japan) Consortium
- 773 0_
- $w MED00173236 $t Cell host & microbe $x 1934-6069 $g Roč. 32, č. 2 (2024), s. 170-180.e12
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38280382 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155736 $b ABA008
- 999 __
- $a ok $b bmc $g 2081248 $s 1216909
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 32 $c 2 $d 170-180.e12 $e 20240126 $i 1934-6069 $m Cell host & microbe $n Cell Host Microbe $x MED00173236
- LZP __
- $a Pubmed-20240412
